72402-14-3

Basic information

• Product Name: Methyl-2,3-O-isopropylidene-D-ribofuranoside
• Synonyms: METHYL 2,3-O-ISOPROPYLIDENE-D-RIBOFURANOSIDE;METHYL 2,3-O-ISOPROPYLIDEN-D-RIBOFURANOSE;METHYL-2,3-O-ISOPROPYLIDENE-ALPHA,BETA-D-RIBOFURANOSIDE;METHYL 2,3-O-ISOPROPYLIDENE-B-D-RIBOFURANOSIDE;[(3aR,4R,6aR)-6-methoxy-2,2-dimethyl-tetrahydro-2H-furo[3,4-d][1,3]dioxol-4-yl]methanol;((3aR,4R,6aR)-6-Methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol
• CAS NO: 72402-14-3
• Molecular Formula: C₉H₁₆O₅
• Molecular Weight: 204.22
• Mol File: 72402-14-3.mol
• Article Data: 45

Chemical Properties

• Boiling Point: 72-75 °C(Press: 0.6 Torr)
• Appearance: /
• Density: 1.23±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.14±0.10(Predicted)
• CAS DataBase Reference: Methyl-2,3-O-isopropylidene-D-ribofuranoside(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl-2,3-O-isopropylidene-D-ribofuranoside(72402-14-3)
• EPA Substance Registry System: Methyl-2,3-O-isopropylidene-D-ribofuranoside(72402-14-3)

Safety Data

• Hazardous Substances Data: 72402-14-3(Hazardous Substances Data)

Usage

Uses

Methyl 2,3-O-Isopropylidene-D-ribofuranoside can be prepared to use as PRMT5 inhibitors.

Upstream product

• 36468-53-8 β-D-ribofuranose 
• 1824-96-0 methyl ribofuranoside 
• 77-76-9 2,2-dimethoxy-propane 
• 67-64-1 acetone 
• 532-20-7 D-Ribose 
• 122-51-0 orthoformic acid triethyl ester 
• 67-56-1 methanol 
• 10257-32-6 D-ribose 
• 50-69-1 D-ribose 
• 144732-43-4 (3aR,6R,6aR)-4-Methoxy-2,2-dimethyl-6-trityloxymethyl-tetrahydro-furo[3,4-d][1,3]dioxole 

Downstream Products

• 459426-88-1 (4R,5R)-5-((S)-2-Benzyloxy-1-hydroxy-2-methyl-propyl)-2,2-dimethyl-[1,3]dioxolane-4-carbaldehyde 
• 459426-89-2 (S)-2-Benzyloxy-1-((4R,5S)-5-hydroxymethyl-2,2-dimethyl-[1,3]dioxolan-4-yl)-2-methyl-propan-1-ol 
• 459426-96-1 2-Benzyloxy-1-((4S,5S)-5-benzyloxymethyl-2,2-dimethyl-[1,3]dioxolan-4-yl)-2-methyl-propan-1-one 
• 459426-91-6 (4S,5S)-4-((S)-2-Benzyloxy-1-methoxy-2-methyl-propyl)-5-benzyloxymethyl-2,2-dimethyl-[1,3]dioxolane 
• 459426-98-3 (4S,5S)-4-((R)-2-Benzyloxy-1-methoxy-2-methyl-propyl)-5-benzyloxymethyl-2,2-dimethyl-[1,3]dioxolane 
• 459426-90-5 (S)-2-Benzyloxy-1-((4R,5S)-5-benzyloxymethyl-2,2-dimethyl-[1,3]dioxolan-4-yl)-2-methyl-propan-1-ol 
• 459426-97-2 (R)-2-Benzyloxy-1-((4R,5S)-5-benzyloxymethyl-2,2-dimethyl-[1,3]dioxolan-4-yl)-2-methyl-propan-1-ol 
• 144993-84-0 methyl 5,6-didehydro-5,6-dideoxy-2,3-O-isopropylidene-D-allofuranoside 
• 345898-95-5 N-(((4S,5R)-2,2-dimethyl-5-vinyl-1 ,3-dioxolan-4-yl)methylene)-1-phenylmethanamine oxide 
• 376608-75-2 2-({(3aR,4S,6R,6aS)-6-[7-chloro-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidine-3-yl]-2,2-dimethyltetrahydro-3aH-cyclopentadiene[d][1,3]dioxolene-4-yl}oxy)ethanol 
• 376608-74-1 2-[((3aR,4S,6R,6aS)-6-[[5-amino-6-chloro-2-(propylsulfanyl)-4-pyrimidinyl]amino]-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy]-1-ethanol 
• 274693-55-9 [3aR-(3aα,4α,6α,6aα)]-2-[[6-amino-2,2-dimethyl tetrahydro-4H-cyclopenta-1,3-dioxol-4-yl]oxy]ethanol 
• 866551-95-3 ethyl 2-(6-(benzyloxycarbonylamino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yloxy) acetate 
• 274693-53-7 [3aS-(3aα,4α,6α,6aα)]-(tetrahydro-6-hydroxy-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl)carbamic acid phenylmethyl ester 

Relevant articles and documents

BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION

The present disclosure provides biomarkers useful as companion diagnostics for detecting glycocalyx-based disease that is amenable to treatment using compounds designed for improving the condition of the glycocalyx and/or reducing inflammation and/or oxidative damage, as well as related compositions, kits, and methods.

Preparation method of ticagrelor key intermediate iodide

The invention discloses a preparation method of ticagrelor key intermediate iodide, which comprises the following steps of: (1) synthesis of an intermediate 1: taking D-ribose as a raw material, methanol and acetone as solvents, adding thionyl chloride as a catalyst, and concentrating to remove the solvents after the reaction is finished, so as to obtain the intermediate 1, and (3) synthesis of the key intermediate iodide: by taking acetonitrile as a solvent, adding the intermediate 1 and sodium iodide into a reaction system, dropwise adding trimethylchlorosilane, adding a small amount of water for quenching reaction after the reaction is finished, evaporating to remove acetonitrile, extracting with the solvent, and concentrating to obtain the key intermediate iodide. According to the preparation method of the ticagrelor key intermediate iodide, in the synthesis process of the intermediate 1, thionyl chloride is adopted to replace hydrochloric acid to serve as a catalyst, the reactionconversion rate is greatly increased, then trimethylchlorosilane/sodium iodide serves as an iodinating agent, the reaction condition is mild, aftertreatment is simple, and the conversion rate is high.

Industrial large-scale production method of capecitabine intermediate

The invention provides an industrial large-scale production method of a capecitabine intermediate. The industrial large-scale production method adopts a one-pot production method of simultaneously adding methanol and acetone, and is a preparation method which is energy-saving, short in production period and high in yield; a method of adding low-boiling-point solvents such as ethyl acetate into dimethyl sulfoxide or pyrrolidone for reflux cooling to take away heat is adopted; and a production method of hydrolyzing while distilling is designed, the methanol and the acetone which are generated byhydrolysis are distilled out, the methanol and the acetone in water are continuously reduced, the reaction is carried out towards K3, and the reaction is complete and thorough.